ERBB2 and breast cancer: For the first time to our knowledge, we directly demonstrate a longitudinal decline in microvascular endothelial function in patients with BC treated with Dox and/or anti-HER2 therapy, which is associated with suppressed NO production, elevated H2O2 levels, and impaired angiogenic potential.